|
|
| 発表論文 |
2024
1) Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources.
Shimizu M, Makiguchi M, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H.
Drug Metab. Pharmacokinet., in press (2024)
2) Progress report of the Tohoku Medical Megabank Community-Based Cohort Study: Study profile of the repeated center-based survey during second period in Miyagi Prefecture.
Hozawa A, Nakaya K, Nakaya N, Nakamura T, Kogure M, Hatanaka R, Chiba I, Kanno I, Sugawara J, Kodama E, Hamanaka Y, Kobayashi T, Uruno A, Tsuchiya N, Hirata T, Narita A, Tsuboi A, Tamahara T, Otsuki A, Goto M, Taira M, Shimizu R, Suzuki K, Obara T, Kikuya M, Metoki H, Ishikuro M, Danjoh I, Ogishima S, Nagaie S, Minegishi N, Hiratsuka M, Kumada K, Nishijima I, Nobukuni T, Yamaguchi-Kabata Y, Nagami F, Kure S, Fuse N, Kinoshita K, Izumi Y, Kuriyama S, Yamamoto M.
J. Epidemiol., in press (2024)
3) Structural Impact Assessment of Cytochrome P450 2A13 Polymorphisms Using Molecular Dynamics Simulations.
Kato K, Nakayoshi T, Hioki S, Hiratsuka M, Ishikawa Y, Kurimoto E, Oda A.
Biol Pharm Bull., 47:620-628 (2024)
4) Caspases downregulate nickel and hydrogen peroxide-induced IL-8 production via modification of c-Jun N-terminal kinases.
Maeyama R, Segawa R, Onodera R, Hiratsuka M, Hirasawa N.
Toxicology 501:153710 (2024)
5) Biological Evaluation of Isosteric Applicability of 1,3-Substituted Cuneanes as m-Substituted Benzenes Enabled by Selective Isomerization of 1,4-Substituted Cubanes.
Fujiwara K, Nagasawa S, Maeyama R, Segawa R, Hirasawa N, Hirokawa T, Iwabuchi Y.
Chem. Eur. J., e202303548 (2024)
6) Effect of N-glycosylation on constitutive signal transduction by mutated cytokine receptor-like factor 2.
Yamamoto R, Segawa R, Liu J, Isaji T, Gu J, Hiratsuka M, Hirasawa N.
Biochim. Biophys. Acta Gen. Subj. 1867:130465 (2023)
7) jMorp: Japanese Multi-Omics Reference Panel update report 2023.
Tadaka S, Kawashima J, Hishinuma E, Saito S, Okamura Y, Otsuki A, Kojima K, Komaki S, Aoki Y, Kanno T, Saigusa D, Inoue J, Shirota M, Takayama J, Katsuoka F, Shimizu A, Tamiya G, Shimizu R, Hiratsuka M, Motoike IN, Koshiba S, Sasaki M, Yamamoto M, Kinoshita K.
Nucleic Acids Res. 52:D622-D632 (2024)
2023
1) Functional characterization of 29 cytochrome P450 4F2 variants identified in a population of 8,380 Japanese subjects and assessment of arachidonic acid ω-hydroxylation.
Sato Y, Hishinuma E, Yamazaki S, Ueda A, Kumondai M, Saito S, Tadaka S, Kinoshita K, Nakayoshi T, Oda A, Maekawa M, Mano N, Hirasawa N, Hiratsuka M.
Drug Metab. Dispos. 51:1561-1568 (2023)
2) Effect of N-glycosylation on constitutive signal transduction by mutated cytokine receptor-like factor 2.
Yamamoto R, Segawa R, Liu J, Isaji T, Gu J, Hiratsuka M, Hirasawa N.
Biochim. Biophys. Acta Gen. Subj. 1867:130465 (2023)
3) Variants of flavin-containing monooxygenase 3 found in subjects in an updated database of genome resources.
Makiguchi M, Shimizu M, Yokota Y, Shimamura E, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H.
Drug Metab. Dispos. 51:884-891 (2023)
4) Hypoxia-inducible factor prolyl hydroxylase inhibitors suppressed thymic stromal lymphopoietin production and allergic responses in a mouse air-pouch-type ovalbumin sensitization model.
Segawa R, Kyoda T, Yagisawa M, Muramatsu T, Hiratsuka M, Hirasawa N.
Int. Immunopharmacol. 118:110127 (2023)
5) Validation of a genotyping technique for a surrogate marker of HLA-B∗58:01 for allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in the Japanese population.
Tsukagoshi E, Nakamura R, Tanaka Y, Maekawa K, Hiratsuka M, Asada H, Saito Y.
Drug Metab. Pharmacokinet. in press (2023)
6) Development of a Simultaneous Liquid Chromatography-Tandem Mass Spectrometry Analytical Method for Urinary Endogenous Substrates and Metabolites for Predicting Cytochrome P450 3A4 Activity.
Kumondai M, Maekawa M, Hishinuma E, Sato Y, Sato T, Kikuchi M, Hiratsuka M, Mano N.
Biol. Pharm. Bull. 46:455-463 (2023)
7) Functional characterization of 12 dihydropyrimidinase allelic variants in Japanese individuals for the prediction of 5-fluorouracil treatment-related toxicity.
Hishinuma E, Narita Y, Gutiérrez Rico EM, Ueda A, Obuchi K, Tanaka Y, Saito S, Tadaka S, Kinoshita K, Maekawa M, Mano N, Nakayoshi T, Oda A, Hirasawa N, Hiratsuka M.
Drug Metab. Dispos. 51:165-173 (2023)
8) Selective induction of thymic stromal lymphopoietin expression by novel nitrogen-containing steroid compounds in PAM-212 cells.
Wang Y, Segawa R, Weng Y, Nakai K, Ohashi K, Hiratsuka M, Arisawa M, Hirasawa N.
J. Translational Autoimmunity 6:100186 (2023)
2022
1) Selective induction of thymic stromal lymphopoietin expression by novel nitrogen-containing steroid compounds in PAM-212 cells.
Wang Y, Segawa R, Weng Y, Nakai K, Ohashi K, Hiratsuka M, Arisawa M, Hirasawa N.
Journal of Translational Autoimmunity 6:10086 (2022)
2) Inhibition of thymic stromal lymphopoietin production by FK3453.
Segawa R, Ishihara R, Hiratsuka M, Hirasawa N.
J. Pharmacol. Sci. 149:198-204 (2022)
3) Further survey of genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found in an updated database of genome resources and identified by phenotyping for trimethylaminuria.
Shimizu M, Hirose N, Kato M, Sango H, Uenuma Y, Makiguchi M, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H.
Drug Metab. Pharmacokinet. 46:100465 (2022)
4) Structural investigation of pathogenic variants in dihydropyrimidinase using molecular dynamics simulations.
Kato K, Nakayoshi T, Nagura A, Hishinuma E, Hiratsuka M, Kurimoto E, Oda A.
J. Mol. Graph. Model. 117:108288 (2022)
5) Importance of rare DPYD genetic polymorphisms for 5-fluorouracil therapy in the Japanese population.
Hishinuma E, Narita Y, Obuchi K, Ueda A, Saito S, Tadaka S, Kinoshita K, Maekawa M, Mano N, Hirasawa N, Hiratsuka M.
Front. Pharmacol. 13:930470 (2022)
6) Rapid genetic diagnosis for Okinawan patients with Pendred syndrome using single-stranded tag hybridization chromatographic printed-array strip.
Ganaha A, Hishinuma E, Kaname T, Hiratsuka M, Kondo S, Tono T.
J. Clin. Med. 11:1099 (2022)
7) Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics.
Siamoglou S, Koromina M, Hishinuma E, Yamazaki S, Tsermpini EE, Kordou Z, Fukunaga K, Chantratita W, Zhou Y, Lauschke V, Mushiroda T, Hiratsuka M, Patrinos GP.
Pharmacol. Res. 176:106087 (2022)
8) A pilot study for return of individual pharmacogenomic results to population-based cohort study participants.
Ohneda K, Hiratsuka M, Kawame H, Nagami F, Suzuki Y, Suzuki K, Sato M, Uruno A, Sakurai-Yageta M, Hamanaka Y, Taira M, Ogishima S, Kuriyama S, Hozawa A, Tomita H, Minegishi N, Sugawara J, Danjo I, Nakamura T, Kobayashi T, Yamaguchi-Kabata Y, Tadaka S, Obara T, Hishinuma E, Mano N, Matsuura M, Sato Y, Honkura Y, Suzuki J, Katori Y, Kakuta Y, Masamune A, Aoki Y, Nakayama M, Kure S, Kinoshita K, Fuse N, Yamamoto M.
Jpn. Med. Assoc. J. 5:177-189 (2022)
9) Effects of Salicylate Derivatives on Localization of p.H723R Pendrin Mutant.
Murakoshi M, Koyama S, Kobayashi T, Usami S, Kamiya K, Ikeda K, Haga Y, Tsumoto K, Nakamura H, Hirasawa N, Ishihara K, Wada H.
Auris Nasus Larynx 49:928-937(2022)
10) Palladium-induced temporal internalization of MHC Class I contributes to T cell-mediated antigenicity.
Ito K, Kanaseki T, Tokita S, Torigoe T, Hirasawa N, Ogasawara K.
Front. Immunol. 12:736936 (2022)
2021
1) A chalcone derivative suppresses TSLP induction in mice and human keratinocytes through binding to BET family proteins.
Segawa R, Takeda H, Yokoyama T, Ishida M, Miyata C, Saito T, Ishihara R, Nakagita T, Sasano Y, Kanoh N, Iwabuchi Y, Mizuguch M, Hiratsuka M, Hirasawa N.
Biochem. Pharmacol. 194:114819 (2021)
2) Deciphering Structural Alterations Associated with Activity Reductions of Genetic Polymorphisms in Cytochrome P450 2A6 Using Molecular Dynamics Simulations.
Kato K, Nakayoshi T, Nokura R, Hosono H, Hiratsuka M, Ishikawa Y, Kurimoto E, Oda A.
Int. J. Mol. Sci. 22:10119 (2021)
3) Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation.
Hiratsuka M, Zhou Y, Lauschke VM.
Front. Genet., doi.org/10.3389/fgene.2021.736626 (2021)
4) Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources.
Shimizu M, Koibuchi N, Mizugaki A, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H.
Drug Metab. Pharmacokinet., 38:100387 (2021)
5) Functional characterization of 21 rare allelic CYP1A2 variants identified in a population of 4773 Japanese individuals by assessing phenacetin O-deethylation.
Kumondai M, Gutiérrez Rico EM, Hishinuma E, Nakanishi Y, Yamazaki S, Ueda A, Saito S, Tadaka S, Kinoshita K, Saigusa D, Nakayoshi T, Oda A, Hirasawa N, Hiratsuka M.
J. Pers. Med. 11:690 (2021)
6) Lactate released from human fibroblasts enhances Ni elution from Ni plate.
Kasai K, Segawa R, Onodera R, Asakawa S, Hiratsuka M, Hirasawa N.
Toxicology, in press (2021)
7) Functional assessment of 12 rare allelic CYP2C9 variants identified in a population of 4773 Japanese individuals.
Kumondai M, Gutiérrez Rico EM, Hishinuma E, Ueda A, Saito S, Tadaka S, Kinoshita K, Nakayoshi T, Oda A, Maekawa M, Mano N, Hirasawa N, Hiratsuka M.
J. Pers. Med. 11:94 (2021)
8) Functional characterization of 40 CYP3A4 variants by assessing midazolam 1'-hydroxylation and testosterone 6β-hydroxylation.
Kumondai M, Gutiérrez Rico EM, Hishinuma E, Ueda A, Saito S, Saigusa D, Tadaka S, Kinoshita K, Nakayoshi T, Oda A, Abe A, Maekawa M, Mano N, Hirasawa N, Hiratsuka M.
Drug Metab. Dispos. 49:212-220 (2021)
9) Improvement of a Rapid and Highly Sensitive Method for the Diagnosis of the Mitochondrial m.1555A>G Mutation Based on a Single-Stranded Tag Hybridization Chromatographic Printed-Array Strip.
Isaka Y, Nishio S, Hishinuma E, Hiratsuka M, Usami S.
Genet. Test. Mol. Biomarkers 25:79-83 (2021)
2020
1) Heterologous expression of high-activity cytochrome P450 in mammalian cells.
Kumondai M, Hishinuma E, Gutiérrez Rico EM, Ito A, Nakanishi Y, Saigusa D, Hirasawa N, Hiratsuka M.
Sci. Rep. 10:14193 (2020)
2) Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population.
Fukunaga K, Hishinuma E, Hiratsuka M, Kato K, Okusaka T, Saito T, Ikeda M, Yoshida T, Zembutsu H, Iwata N, Mushiroda T.
J. Hum. Genet. 66:139-149 (2020)
3) CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity.
Gutiérrez EM, Kikuchi A, Saito T, Kumondai M, Hishinuma E, Kaneko A, Chan CW, Gitaka J, Nakayoshi T, Oda A, Saito S, Hirasawa N, Hiratsuka M.
Drug Metab. Pharmacokinet. 35:89-101 (2020)
4) Potential synergistic effects of novel hematopoietic prostaglandin D synthase inhibitor TAS-205 and different types of anti-allergic medicine on nasal obstruction in a guinea pig model of experimental allergic rhinitis.
Aoyagi H, Kajiwara D, Tsunekuni K, Tanaka K, Miyoshi K, Hirasawa N.
Eur J. Pharmacol. 875:173030 (2020)
5) ATP-Binding Cassette Transporter C4 is a Prostaglandin D2 Exporter in HMC-1 cells.
Tanaka N, Kawai J, Hirasawa N, Mano N, Yamaguchi H
Prostaglandins, Leukotrienes and Fatty Acids , 159, 102139 (2020)
6) Suprabasin‐null mice retain skin barrier function and show high contact hypersensitivity to nickel upon oral nickel loading.
Nakazawa S, Shimauchi T, Funakoshi A, Aoshima M, Phadungsaksawasdi P, Sakabe J, Asakawa S, Hirasawa N, Ito T, Tokura Y
Sci. Rep. 10:14559 (2020)
2019
1) Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database.
Shimizu M, Yoda H, Nakakuki K, Saso A, Saito I, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H.
Drug Metab. Pharmacokinet. 34:334-339 (2019)
2) COX-2 induces T cell accumulation and IFN-γ production during the development of chromium allergy.
Sitalaksmi RM, Ito K, Ogasawara K, Suto Y, Itabashi M, Ueda K, Hirasawa N, Narushima T, Hendrijantini N, Kresnoadi U, Sasaki K.
Autoimmunity 52:228-234 (2019)
3) Hypoxia inhibits TNF-α-induced TSLP expression in keratinocytes.
Tashiro N, Segawa R, Tobita R, Asakawa S, Mizuno N, Hiratsuka M, Hirasawa N.
PLoS ONE 14(11):e0224705 (2019)
4) Grifola frondosa extract and ergosterol reduce allergic reactions in an allergy mouse model by suppressing the degranulation of mast cells.
Kawai J, Mori K, Hirasawa N.
Biosci Biotechnol Biochem. 83:2280-2287 (2019)
5) A steroid alkaloid derivative 02F04 upregulates thymic stromal lymphopoietin expression slowly and continuously through a novel Gq/11-ROCK-ERK1/2 signaling pathway in mouse keratinocytes.
Weng Y, Wang J, Yang Z, Xi M, Duan J, Guo C, Yin Y, Segawa R, Moriya T, Yonezawa T, Cha BY, Woo JT, Wen A, Hirasawa N.
Cell Signal. 57:58-64 (2019)
6) A chalcone derivative suppresses the induction of TSLP in mice and human keratinocytes and attenuates OVA-induced antibody production in mice.
Segawa R, Shiraki M, Sudo S, Shigeeda K, Saito T, Mizuno N, Moriya T, Yonezawa T, Woo JT, Hiratsuka M, Hirasawa N.
Eur J Pharmacol. 10;851:52-62 (2019)
7) An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke V.
Pharmacogenomics J. 19:115–126 (2019)
2018
1) Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation.
T. Watanabe, T. Saito, EM. Gutierrez Rico, E. Hishinuma, M. Kumondai, M. Maekawa, A. Oda, D. Saigusa, S. Saito, J. Yasuda, M. Nagasaki, N. Minegishi, M. Yamamoto, H. Yamaguchi, N. Mano, N. Hirasawa, M. Hiratsuka.
Biochem. Pharmacol. 156:420-430 (2018)
2) Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.
T. Saito, EM. Gutierrez Rico, A. Kikuchi, A. Kaneko, M. Kumondai, F. Akai, D. Saigusa, A. Oda, N. Hirasawa, M. Hiratsuka.
Drug Metab. Pharmacokinet. 33:250-257 (2018)
3) Development and application of a rapid and sensitive genotyping method for pharmacogene variants using the single-stranded tag hybridization chromatographic printed-array strip (STH-PAS).
M. Kumondai, A. Ito, E. Hishinuma, A. Kikuchi, T. Saito, M. Takahashi, C. Tsukada, S. Saito, J. Yasuda, M. Nagasaki, N. Minegishi, M. Yamamoto, A. Kaneko, I. Teramoto,M. Kimura, N. Hirasawa, M. Hiratsuka.
Drug Metab. Pharmacokinet. 33:258-263 (2018)
4) Ergosterol and its derivatives from Grifola frondosa inhibit antigen-induced degranulation of RBL-2H3 cells by suppressing the aggregation of high affinity IgE receptors.
J. Kawai, Y. Higuchi, M. Hirota, N. Hirasawa, K. Mori.
Biosci. Biotechnol. Biochem.82:1803-1811 (2018)
5) Functional characterization of CYP2D7 gene variants.
MM. Jukic, VM. Lauschke VM, T. Saito, M. Hiratsuka, M. Ingelman-Sundberg.
Pharmacogenomics 19:931-936 (2018)
6) Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1,070 Japanese individuals.
E. Hishinuma, Y. Narita, S. Saito, M. Maekawa, F. Akai, Y. Nakanishi, J. Yasuda, M. Nagasaki, M. Yamamoto, H. Yamaguchi, N. Mano, N. Hirasawa, M. Hiratsuka.
Drug Metab. Dispos. 46:1083-1090 (2018)
7) All-trans retinoic acid enhances antibody production by inducing the expression of thymic stromal lymphopoietin protein.
T. Hatayama, R. Segawa, N. Mizuno, S. Eguchi, H. Akamatsu, M. Fukuda, F. Nakata, WJ. Leonard, M. Hiratsuka, N. Hirasawa.
J. Immunol. 200:2670-2676 (2018)
8) Rapid and sensitive multiplex single-tube nested PCR for the identification of five human Plasmodium species.
T. Saito, A. Kikuchi, A. Kaneko, R. Isozumi, I. Teramoto, M. Kimura, N. Hirasawa, M. Hiratsuka.
Parasitol. Int. 67:277-283 (2018)
9) Zinc ions attenuate Ni ion-induced inflammation.
R. Onodera, S. Asakawa, R. Segawa, N. Mizuno, K. Ogasawara, M. Hiratsuka, N. Hirasawa.
Sci. Rep. 8:2911. doi: 10.1038/s41598-018-21014-8 (2018)
10) Nickel ions bind to HSP90β and enhance HIF-1α-mediated IL-8 expression.
S. Asakawa, R. Onodera, Y. Kishimoto, T. Sato, R. Segawa, N. Mizuno, K. Ogasawara, T. Moriya, M. Hiratsuka, N. Hirasawa.
Toxicology 395:45-53 (2018)
11) Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation.
M. Kumondai, H. Hosono, M. Maekawa, H. Yamaguchi, N. Mano, A. Oda, N. Hirasawa, M. Hiratsuka.
Drug Metab. Pharmacokinet. 33:82-89 (2018)
12) EGFR transactivation is involved in TNF-α-induced expression of thymic stromal lymphopoietin expression in human keratinocyte cell line.
R. Segawa, K. Shigeeda, T. Hatayama, M. Shiraki, N. Mizuno, T. Moriya, M. Hiratsuka, N. Hirasawa.
J. Dermatol. Sci. 89:290-298 (2018)
13) Induction of thymic stromal lymphopoietin by a steroid alkaloid derivative in mouse keratinocytes.
Y. Weng, N. Mizuno, J. Dong, R. Segawa, T. Yonezawa, B. Y. Cha, J.T. Woo, T. Moriya, M. Hiratsuka, N. Hirasawa.
Int. Immunopharm. 55:28-37 (2018)
14) LPS priming in early life decreases antigen uptake of dendritic cells via NO production.
N. Mizuno, Y. Sasaki, R. Segawa, S. Asakawa, M. Hiratsuka, N. Hirasawa.
Immunobiol. 223:25-31 (2018)
15) Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics.
M. Santos, M. Niemi, M. Hiratsuka, M. Kumondai, M. Ingelman-Sundberg, VM. Lauschke, C. Rodriguez-Antona.
Genet. Med. 20:622-629 (2018)
2017
1) Pentanoic acid induces thymic stromal lymphopoietin production through Gq/11 and Rho-associated protein kinase signaling pathway in keratinocytes.
N. Mizuno, K. Abe, Y. Morishita, S. Yamashita, R. Segawa, J. Dong, T. Moriya, M. Hiratsuka, N. Hirasawa.
Int. Immunopharm. 50:216-223 (2017)
2) Influence of Japanese regulatory action on denosumab-related hypocalcemia using Japanese Adverse Drug Event Report database.
M. Takeyama, K. Sai, T. Imatoh, K. Segawa, N. Hirasawa, Y. Saito.
Biol. Pharm. Bull. 40:1447-1453 (2017)
3) Functional characterization of 21 allelic variants of dihydropyrimidinase.
E. Hishinuma, F. Akai, Y. Narita, M. Maekawa, H. Yamaguchi, N. Mano, A. Oda, N. Hirasawa, M. Hiratsuka.
Biochem. Pharmacol. 143:118-128 (2017)
4) Investigation of substrate recognition for cytochrome P450 1A2 mediated by water molecules using docking and molecular dynamics simulations.
Y. Watanabe, S. Fukuyoshi, K. Kato, M. Hiratsuka, N. Yamaotsu, S. Hirono, H. Gouda, A. Oda.
J. Mol. Graph. Model. 74:326-336 (2017)
5) Pregnenolone 16α-carbonitrile amelirorates concanavalin A-induced liver injury in mice independent of the nuclear receptor PXR activation.
S. Kodama, T. Shimura, H. Kuribayashi, T. Abe, K. Yoshinari.
Toxicol. Lett. 271:58-65 (2017)
6) Licochalcones extracted from Glycyrrhiza inflate inhibit platelet aggregateon accompanied by inhibition of COX-1 activity.
A. Okuda-Tanino, D. Sugawara, T. Tashiro, M. Iwashita. Y. Obara, T. Moriya, C. Tsushima, D. Saigusa, Y. Tomioka, K. Ishii, N. Nakahata.
PLoS One 12(3) e0173628 (2017)
7) Induced histamine regulates Ni elution from an implanted Ni wire in mice by downregulating neutrophil migration.
Y. Kishimoto, S. Asakawa, T. Sato, T. Takano, T. Nakajyo, N. Mizuno, R. Segawa, T. Yoshikawa, M. Hiratsuka, K. Yanai, H. Ohtsu, N. Hirasawa.
Experimental Dermacology 26:868-874 (2017)
8) Functional characterization of 34 CYP2A6 allelic variants by assessment of nicotine C- oxidation and coumarin 7-hydroxylation activities.
H. Hosono, M. Kumondai, M. Maekawa, H. Yamaguchi, N. Mano, A. Oda, N. Hirasawa, M. Hiratsuka.
Drug Metab. Dispos. 45:279-285 (2017)
9) Down-regulation of Na+/H+ exchanger 1 by Toll-like receptor stimulation in macrophages.
S. Takakuwa, N. Mizuno, T. Takano, S. Asakawa, T. Sato, M. Hiratsuka, N. Hirasawa.
Immunobiology 222:176-182 (2017)
10) Activation of nuclear receptor CAR by an environmental pollutant perfluorooctanoic acid.
T. Abe, M. Takahashi, M. Kano, Y. Amaike, C. Ishii, K. Maeda, Y. Kudoh, T. Morishita, T. Hosaka, T. Sasaki, S. Kodama, A. Matsuzawa, H. Kojima, K. Yoshinari.
Arch Toxicol. 91:2365-2374 (2017)
2016
1) Non-24-hour sleep?wake syndrome improved by low-dose valproic acid: a case report.
M. Kurita, T. Moriya, S. Nishino, E. Hirata, N. Hirasawa, Y. Okubo, T. Sato.
Neuropsychiatric Disease and Treatment 12:3199-3203 (2016)
2) Involvement of COX-2 in nickel elution from a wire implanted subcutaneously in mice.
T. Sato, Y. Kishimoto, S. Asakawa, N. Mizuno, M. Hiratsuka, N. Hirasawa.
Toxicology 363-364:37-40 (2016)
3) CYP2A13 genetic polymorphisms in relation to the risk of bladder cancer in Japanese smokers.
M. Kumondai, H. Hosono, K. Orikasa, Y. Arai, T. Arai, H. Sugimura, S. Ozono, T. Sugiyama, T. Takayama, T. Sasaki, N. Hirasawa, M. Hiratsuka.
Biol. Pharm. Bull. 39:1683-1686 (2016)
4) Prediction of three-dimensional structures and structural flexibilities of wild-type and mutant cytochrome P450 1A2 using molecular dynamics simulations.
Y. Watanabe, S. Fukuyoshi, M. Hiratsuka, N. Yamaotsu, S. Hirono, O. Takahashi, A. Oda.
J Mol Graph Model. 68:48-56 (2016)
5) Lipopolysaccharide-Activated Leukocytes Enhance Thymic Stromal Lymphopoietin Production in a Mouse Air-Pouch-Type Inflammation Model.
R. Segawa, N. Mizuno, T. Hatayama, D. Jiangxu, M. Hiratsuka, Y. Endo, N. Hirasawa.
Inflammation 39:1527-1537 (2016)
6) PXR stimulates growth factor-mediated hepatocyte proliferation by cross-talk with the FOXO transcription factor.
R. Shizu, T. Abe, S. Benoki, M. Takahashi, S. Kodama, M. Miayata, A. Matsuzawa, K. Yoshinari.
Biochem J. 473:257-266 (2016)
7) Inhibitory effects of nicotine derived from cigarette smoke on thymic stromal lymphopoietin production in epidermal keratinocytes.
J. Dong, R. Segawa, N. Mizuno, M. Hiratsuka, N. Hirasawa.
Cell Immunol. 302:19-25 (2016)
8) Genetic polymorphisms of CYP2A6 in a case-control study on bladder cancer in Japanese smokers.
M. Kumondai, H. Hosono, K. Orikasa, Y. Arai, T. Arai, H. Sugimura, S. Ozono, T. Sugiyama, T. Takayama, T. Sasaki, N. Hirasawa, M. Hiratsuka.
Biol. Pharm. Bull. 39:84-89 (2016)
2015
1) Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
C. Tsukada, T. Saito, M. Maekawa, N. Mano, A. Oda, N. Hirasawa, M. Hiratsuka.
Drug Metab.& Pharmacokin. 30:366-373 (2015)
2) CYP2A6 genetic polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers.
H. Hosono, M. Kumondai, T. Arai, H. Sugimura, T. Sasaki, N. Hirasawa, M. Hiratsuka.
Drug Metab.& Pharmacokin. 30:263-268 (2015)
3) Genetic polymorphisms of dihydropyrimidinase gene in a Japanese patient with capecitabine-induced toxicity.
M. Hiratsuka, H. Yamashita, F. Akai, H. Hosono, E. Hishinuma, N. Hirasawa, T. Mori.
PLoS One 10, e0124818 (2015)
4) Functional characterization of 20 allelic variants of CYP1A2.
M. Ito, Y. Katono, A. Oda, N. Hirasawa, M. Hiratsuka.
Drug Metab.& Pharmacokin. 30:247-252 (2015)
5) Intrinsic atopic dermatitis shows high serum nickel concentration.
H. Yamaguchi, N. Hirasawa, S. Asakawa, K. Okita, Y. Tokura.
Allergol. Int. 64:282-284 (2015)
6) Nickel ions selectively inhibit lipopolysaccharide-induced interleukin-6 production by decreasing its mRNA stability.
S. Asakawa, Y. Kishimoto, T. Takano, K. Okita, S. Takakuwa, T. Sato, M. Hiratsuka, O. Takeuchi, N. Hirasawa.
PLoS One 10, e0119428 (2015)
7) Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal L-cells.
T. Sato, H. Hayashi, M. Hiratsuka, N. Hirasawa N.
Mol. Cell. Endocrinol. 406:60-67 (2015)
8) The anti-inflammatory effects of Hericium einaceus in a coculture system of 3T3-L1 adipocytes and RAW264 macrophages.
K. Mori, K. Ouchi, N. Hirasawa.
Int. J. Med. Mushrooms 17:609-618 (2015)
9) Functional characterization of 10 CYP4A11 allelic variants to evaluate the effect of genotype on arachidonic acid ω-hydroxylation.
T. Saito, M. Honda, D. Saigusa, N. Suzuki, Y. Tomioka, N. Hirasawa, M. Hiratsuka.
Drug Metab.& Pharmacokin. 30:119-122 (2015)
10) Novel single nucleotide polymorphisms of the dihydropyrimidinase gene (DPYS) in Japanese individuals.
F. Akai, H. Hosono, N. Hirasawa, M. Hiratsuka.
Drug Metab.& Pharmacokin. 30:127-129 (2015)
11) Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation.
M. Takahashi, T. Saito, M. Ito, C. Tsukada, Y. Katono, H. Hosono, M. Maekawa, M. Shimada, N. Mano, A. Oda, N. Hirasawa, M. Hiratsuka.
Pharmacogenomics J. 15:26-32 (2015)
2014
1) Evaluation of influence of single nucleotide polymorphisms in cytochrome P450 2B6 on substrate recognition using computational docking and molecular dynamics simulation.
K. Kobayashi, O. Takahashi, M. Hiratsuka, N. Yamaotsu, S. Hirono, Y. Watanabe, A. Oda.
PLoS One 9, e96789 (2014)
2) Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity.
Y. Muroi, T. Saito, M. Takahashi, K. Sakuyama, Y. Niinuma, M. Ito, C. Tsukada, K. Ohta, Y. Endo, A. Oda, N. Hirasawa, M. Hiratsuka.
Drug Metab.& Pharmacokin. 29:360-366 (2014)
3) Regulation of dipeptidyl peptidase IV in adipocytes by glucose.
S. S．Das, H. Hayashi, T. Sato, R. Yamada, M. Hiratsuka, N. Hirasawa
Diabetes, Metabolic Syndrome and Obesity: Target and Therapy 24:185-194 (2014)
4) Glucagon-like peptide-1 production in the GLUTag cell line is impaired by free fatty acids via endoplasmic reticulum stress.
H. Hayashi, R. Yamada, S. S．Das, T. Sato, A. Takahashi, M. Hiratsuka, N. Hirasawa
Metabolism 63:800-811 (2014)
5) Enhancement of granbule maturation requires histamine synthesis in murine mast cells.
S. Nakazawa, M. Sakanaka, K. Furuta, M. Natsuhara, H. Takano, S. Tsuchitya, Y. Okuno, H. Ohtsu, M. Nishibori, RL. Thurmond, N. Hirasawa, K. Nakayama, A. Ichikawa, Y. Sugimoto, S. Tanaka
Eur J. Immunol. 44: 204-214 (2014)
6) Functional characterization of 32 CYP2C9 allelic variants.
Yui Niinuma, Takahiro Saito, Masamitsu Takahashi, Chiharu Tsukada, Miyabi Ito, Noriyasu Hirasawa, Masahiro Hiratsuka.
Pharmacogenomics J. 14: 107-114 (2014)
7) Identification of a cell line producing high levels of TSLP: Advantages for screening of anti-allergic drugs.
R. Segawa, S. Yamashita, N. Mizuno, M. Shiraki, T. Hatayama, N. Satou, M. Hiratsuka, M. Hide, N. Hirasawa
J. Immunol. Methods 402: 9-14 (2014)
2013
1) High frequencies of positive nickel/cobalt patch tests and high sweat nickel concentration in patients with intrinsic atopic dermatitis.
Yamaguchi, H., Kabashima-Kudo, R., Bito, T., Sakabe, J.-I., Shimauchi, T., Ito, T., Hirakawa, S., Hirasawa, N., Ogasawara, K. Tokura, Y.
J. Dermal. Sc.i72: 240-245 (2013)
2) Evaluation of personal dose equivalent using optically stimulated luminescent dosemeters in Marumori after the Fukushima nuclear accident.
Yoshida-Ohuchi H, Hirasawa N, Kobayashi I, Yoshizawa T
Radiat Prot Dosimetry 154: 385-390 (2013)
3) Induction of thymic stromal lymphopoietin production by nonanoic acid and exacerbation of allergic inflammation in mice.
Yamashita, S., Segawa, R., Satou, N., Hiratsuka, M., Leonard, W.J., Hirasawa, N.
Allergol. Int. 62: 463-471 (2013)
4) Enhancement of inflammatory protein expressions and nuclear factor kB (NF-kB) activity by trichostatin A (TSA) in OP9 preadipocytes.
Sato, T., Kotake, D., Hiratsuka, M., Hirasawa, N.
PLOS One 8(3): e59702 (2013)
5) Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 adipocytes.
Kotake, D., Hirasawa, N.
Eur. J. Pharmacol. 707: 95-103 (2013)
2012
1) The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in Nc/Nga mice.
Ohsawa, Y., Hirasawa, N.
Allergy 67: 1014-1022 (2012)
2) Induction of thymic stromal lymphopoietin production by xylene and exacerbation of picryl chloride-induced allergic inflammation in mice
Satou,N., Ishihara, K., Hiratsuka, M., Tanaka, H., Endo, Y., Saito, S., Iwatate, Y., Leonard, W.J., Hirasawa, N.
Int. Arch. Allergy Immunol. 157: 194-201 (2012)
3) Influence of sex on propofol metabolism, a pilot study: implications
for propofol anesthesia.
I Loryan, M Lindqvist, I Johansson, M Hiratsuka, I van der Heiden, R HN van Schaik, J Jakobsson, M Ingelman-Sundberg.
Eur. J. Clin. Pharmacol., 68, 397-406 (2012)
4) Hetero-oligomerization between adenosine A1 and thromboxane A2 receptors
affects cellular signal transduction on stimulation with high and low concentrations
of agonists for both receptors
Mizuno, M., Suzuki,T., Hirasawa, N., Nakahata, N.
Eur. J. Pharmacol. 677, 5-14 (2012)
2011
1) Novel Single Nucleotide Polymorphism of the CYP2A13 gene in Japanese
individuals,
Y Tamaki, M Honda, Ya Muroi, T Arai, H Sugimura,
Y Matsubara S Kanno, M Ishikawa, N Hirasawa, M Hiratsuka.
Drug Metabolism & Pharmacokinetics, 26, 544-547 (2011)
2) Association between Cancer Risk and Drug Metabolizing Enzyme Gene (CYP2A6,
CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) Polymorphisms in Japanese Cases
of Lung Cancer,
Yuichiro Tamaki, Tomio Arai, Haruhiko Sugimura, Takamitsu Sasaki, Masashi
Honda, Yuka Muroi, Yoichi Matsubara, Shuichi Kanno, Masaaki Ishikawa, Noriyasu Hirasawa, Masahiro Hiratsuka.
Drug Metabolism & Pharmacokinetics, 26, 516-522 (2011)
3) Functional characterization of CYP2B6 allelic variants in demethylation
of anti-malarial artemether.
Masashi Honda, Yuka Muroi, Yuichiro Tamaki, Daisuke Saigusa, Naoto Suzuki,
Yoshihisa Tomioka, Yoichi Matsubara, Akifumi Oda, Noriyasu Hirasawa, Masahiro Hiratsuka.
Drug Metab. Dispos., 39, 1860-1865 (2011)
4) Assessment of the release of nickel from biomaterials in vivo and in
vitro: enahancement by lipopolysaccharide.
Tanaka, R., Goi, Y., Ishihara, K., Ueda, K., Narushima, T., Ohtsu, H.,
Ohuchi, K., Hiratsuka, M., Hirasawa, N.
Inflammation & Regeneration, 31, 302-306 (2011)
5) Enhancement of nickel elution by lipopolysaccharide-induced inflammation
Tanaka, R., Goi, Y., Ishihara, K., Ueda, K., Narushima, T., Ohtsu, H.,
Hiratsuka, M., Hirasawa, N.
J. Dermatol. Sci., 62, 50-57 (2011)
6) Suppression of intracellular calcium levels and inhibition of degranulation
in RBL-2H3 mast cells by the sesquiterpene lactone parthenolide
Hong, J., Aoyama, S., Hirasawa, N., Zee, O., Ishihara, K., Hashida, C., Kimura, M., Seyama, T., Ohuchi, K.
Planta Medica, 77, 252-256 (2011)
7) Induction of thymic stromal lymphopoietin by chemical compounds in vivo
and exacerbation of allergy.
Sato N, Ishihara K, Hiratsuka M, Hirasawa N.
Inflammation & Regeneration., 31, 184-188 (2011)
2010
1) Salicylate restores transport function and anion exchanger activity
of missense pendrin mutations
Ishihara, K., Okuyama, S., Kumano, S., Iida, K., Hamana, H., Murakoshi,
M., Kobayashi, T., Usami, S., Ikeda, K., Haga, Y., Tsumoto, K., Nakamura,
H., Hirasawa, N., Wada, H.
Hearing Research, 270, 110-118 (2010)
2) Functional characterization of genetic polymorphisms identified in
the promoter region of the xanthine oxidese gene.
Kudo M, Sasaki T, Ishikawa M, Hirasawa N, Hiratsuka M.
Drug Metab.& Pharmacokin. 25, 599-604 (2010)
3) Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28,
except CYP2B6.22).
Watanabe T, Sakuyama K, Sasaki T, Ishii Y, Ishikawa M, HirasawaN, Hiratsuka M.
Pharmacogenet. Genom., 20, 459-462 (2010)
4) Kinetics of 6-thioxanthine metabolism by allelic variants of xanthine
oxidase.
Kudo M, Sasaki T, Ishikawa M, Hirasawa N, Hiratsuka M.
Drug Metab.& Pharmacokin.., 25, 361-366 (2010)
2009
1) Enhancement of ligand-dependent down-regulation of glucocorticoid receptor
by lipopolysaccgaride.
Hirasawa N, Yashima K, Ishihara K.
Life Sci., 85, 578-584 (2009)
2) Involvement of prostaglandins and histamine in Nickel wire-induced
acute inflammation in mice.
Hirasawa N, Goi Y, Tanaka R, Ishihara K, Ohtsu H, Ohuchi K.
J. Biomedical Materials Research Part A., 93, 1306-1311 (2009)
3) Suppression of the Antigen-Stimulated RBL-2H3 Mast Cell Activation
by Artekeiskeanol A.
Hong J.J., Sasaki H, Hirasawa N, Ishihara K, Kwak J.H., Zee O., Schmitz F.J., Seyama T, Ohuchi K.
Planta Med., 75, 1494-1498 (2009)
4) Genetic variations in the HGPRT, ITPA, IMPDH1, IMPDH2, and GMPS genes
in Japanese individuals.
Kudo M, Saito Y, Sasaki T, Akasaki H, Yamaguchi Y, Uehara M, Fujikawa K, Ishikawa M, Hirasawa N, Hiratsuka M.
Drug Metab.& Pharmacokin.., 24, 557-564 (2009)
5) Establishment of modified allergic dermatitis model in mouse ear lobes
by application with 12-O-tetradecanoyl phorbol 13-acetate: putative involvement
of thymic stromal lymphopoietinand participation of histamine.
Hirasawa N, Ohsawa Y, Ishihara K, Seyama T, Hong J.J., Ohuchi K.
J. Pharmacol. Sci., 110, 245-250 (2009)
6) Effects of Nickel on the Eosinophil Survival.
Ishihara K, Goi Y, Hong J.J., Seyama T, Ohtsu H. Wada H, Ohuchi K, Hirasawa N.
Int. Arch. Allergy Immunol., 149 Suppl 1: 57-60 (2009)
7) Modification of Picryl Chloride-Induced Allergic Dermatitis Model in
Mouse Ear Lobes by 12-O-Tetradecanoylphorbol 13-Acetate, and Analysis for
Roles of Histamine in the Modified Model.
Hirasawa N, Ohsawa Y, Katoh G, Shibata K, Ishihara K, Seyama T, Tamura S, Hong J,
Ohuchi K.
Int. Arch. Allergy Immunol., 148, 279-288 (2009)
2008
1) Mechanisms for the proliferation of eosinophilic leukemia cells by
FIP1L1-PDGFRa.
Ishihara K, Kitamura H, Hiraizumi K, Kaneko M, Takahashi A, Zee, O.P.,
Hong J.J., Ohuchi K, Hirasawa N.
Biochem. Biophys. Res. Commun., 366, 1007-1011 (2008)
2) Mechanism for the decrease in the FIP1L1-PDGFRa protein level in EoL-1
cells by histone deacetylase inhibitors.
Ishihara K, Kaneko M, Kitamura H, Takahashi A, Hong J, Seyama T, Iida
K, Wada H, Hirasawa N, Ohuchi K.
Int. Arch. Allergy Immunol,, 146(suppl), 7-10 (2008)
3) Effects of Hyperin, Isoquercitrin and Quercetin on Lipopolysaccharide-Induced
Nitrite Production in Rat Peritoneal Macrophage.
Lee S, Park H.-S., Notsu Y, Hyun Ban, H.S., Kim Y.P., Ishihara K, Hirasawa N, Jung S.H., Lee Y.S., Lim S.S.,
Park E.-H., Shin K.H., Seyama T., Hong J.J., Ohuchi K.
Phytotherapy Research., 366, 1007-1011 (2008)
4) Anti-inflamamtory effects of Na+/H+ exchanger inhibitors
Hirasawa N, Kamachi F, Yanai M, Ban H.S., Ishihara K, Seyama T, Hong J.J., Ohuchi K.
Inflam. Regener., 28, 155-159 (2008)
5) Lead compounds for anti-inflammatory drugs isolated from the plants
of the traditional oriental medicine in Korea.
Hong J.J., Shin K.H., Lim S.S., Kwak J.H., Zee O.P., Ishihara K, Hirasawa N, Seyama T, Ohuchi K.
Inflammation & Allergy - Drug Targets., 7, 195-202 (2008)
6) Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2,10,
14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
K Sakuyama, T Sasaki, S Ujiie, K Obata, M Mizugaki, M Ishikawa, M Hiratsuka.
Drug Metab. Dispos., 36, 2460-7 (2008)
7) Possible relation between the risk of Japanese bladder cancer cases
and CYP4B1 genotype.
T Sasaki, M Horikawa, K Orikasa, M Sato, Y Arai, Y Mitachi, M Mizugaki, M Ishikawa, M Hiratsuka.
Jpn. J. Clin. Oncol., 38, 634-640 (2008)
8) Functional characterization of 23 allelic variants of thiopurine S-methyltransferase
gene (TPMT*2 - *24).
S Ujiie, T Sasaki, M Mizugaki, M Ishikawa, M Hiratsuka.
Pharmacogenet. Genom., 18, 887-893 (2008)
9) Generation of mice transgenic for human CYP2C18 and CYP2C19. Characterization
of the sexually dimorphic gene- and enzyme expression.
S Lofgren, RM Baldwin, M Hiratsuka, A Lindqvist, A Carlberg. SC Sim, M Schuke, M Snait, A Edenro, R Fransson-Steen,
Y Terelius, M Ingelman-Sundberg.
Drug Metab. Dispos.., 36, 955-962 (2008)
10) Functional characterization of human xanthine oxidase allelic variants.
M Kudo, T Moteki, T Sasaki, Y Konno, S Ujiie, A Onose, M Mizugaki, M
Ishikawa, M Hiratsuka.
Pharmacogenet. Genom., 18, 243-251 (2008)
11) Genetic polymorphisms and haplotype structures of the human CYP2W1
gene in a Japanese population.
Y Hanzawa, T Sasaki, M Mizugaki, M Ishikawa, M Hiratsuka.
Drug Metab. Dispos.., 36, 349-352 (2008)
総説
2023
2022
1) がん化学療法におけるファーマコゲノミクス - 薬物代謝酵素の遺伝子多型にフォーカスして
平塚真弘
医学のあゆみ、283(7):696-700 (2022)
2) 最近のアトピー性皮膚炎の外用療法 ―デルゴシチニブ軟膏の作用機序を中心に―
平澤典保、舘野実、谷本敦男、北島裕之
新薬と臨床 71:1287-1298 (2022)
3) ステロイド薬の種類
平澤典保
周産期医学 52: 5-9 (2022)
2021
1) 特集：遺伝子診断の現状と未来：ファーマコゲノミクス-ゲノム薬理学
平塚真弘
日本医師会雑誌、149(11):1981-1984 (2021)
2020
1) In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase.
Hishinuma E, Gutiérrez Rico E, Hiratsuka M.
J Clin Med., 9:E2342 (2020)
2019
1) 日本人を主対象とした「医薬品の非臨床及び臨床第Ⅰ相試験における遺伝子多型評価のための科学的情報」の取りまとめと今後の展望
平塚真弘、平澤典保、大島吉輝、児玉進、宮田敏男、段孝、高徳敬之、栗林秀明、中村亮介、斎藤嘉朗
レギュラトリーサイエンス学会誌、9:95-102 (2019)
2) Expression of Histidine Decarboxylase and Its Roles in Inflammation.
N. Hirasawa
Int J Mol Sci., 16;20(2):E376 (2019)
2018
1) ステロイドとは何かー基本と薬効
平澤典保
成人病と生活習慣病 (The Journal of Adult Diseases) 48:1173-1178 (2018)
2) アレルギー炎症による痒みのメカニズム：ヒスタミンの役割
平澤典保
神経内科（Neurological Medicine） 89:50-55 (2018)
3) Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
M. Hiratsuka, N. Hirasawa, Y. Oshima, S. Kodama, T. Miyata, T. Dan, H. Takatoku, H. Kuribayashi, R. Nakamura, Y. Saito.
Drug Metab. Pharmacokinet., 33:141-149 (2018)
2017
1) 特集：日本薬学会第137年会シンポジウム、個別化薬物療法を目指した日本人全ゲノムリファレンスパネルによるリアルワールドデータ解析
平塚真弘
薬学図書館、62(4):206-210 (2017)
2) 特集・感染症診療を変える新しい診断技術・検査法、核酸クロマトグラフィー法
平塚真弘、齋藤雄大
化学療法の領域 33:87-95 (2017)
3) 金属炎症の分子機構
浅川三喜、平澤典保
炎症と免疫 25:87-92 (2017)
2016
1) アレルギーの仕組みと対策
平澤典保
日本薬用植物友の会会報(Japan Association for Herbs News) 120:5-8 (2016)
2) Genetic polymorphisms and in vitro functional characterization of CYP2C8, CYP2C9, and CYP2C19 allelic variants
Masahiro Hiratsuka
Biol. Pharm. Bull. 39:1748-1759 (2016)
2015
1) 重篤副作用に関する予測ゲノムマーカー
斎藤嘉朗, 児玉進, 杉山永見子, 中村亮介
薬学雑誌 135:589-595 (2015)
2014
1) The role of histamine H1 and H4 receptors in atopic detmatitis; from basic research to clinical study
Yusuke Ohsawa and Noriyasu Hirasawa
Allergol. Int. 63:533-542 (2014)
2) ステロイド薬の作用機序と最近の知見
平澤典保
皮膚病診療(Practical Dermatology)36: 799-806 (2014)
3) ファーマコゲノミクス（PGx）情報を利用した個別化薬物療法の展開
平塚真弘
生物物理化学 58:1-4 (2014)
4) Exacerbation of allergic diseases by chemicals: Role of thymic stromal lymphopoietin
Segawa, R. and Hirasawa, N.
J. Pharmacol. Sci. 124:301-306 (2014)
5) TSLP-好塩基球反応軸
畑山昂大、平澤典保
日本薬理学雑誌 143:103-104 (2014)
6) Retinoid signaling on pathological remodeling from view of cardiovascular disease
Daisuke Kotake, Taiki Sato, Noriyasu Hirasawa
Eur. J. Pharmacol.,729: 144-147 (2014)
2013
1) Biochemical assay of G protein-coupled receptor-oligomerization: Adenosine A1 and thromboxane A2 receptors form the novel functional hetero-oligomer
Natsumi Mizuno, Tokiko Suzuki, Yu Kishimoto, Noriyasu Hirasawa
Methods Cell Biol 117:213-227 (2013)
2) 研究戦略YAKU学-研究現場から臨床へ-、PGx情報を利用した個別化薬物療法の展開
平塚真弘
薬事日報 第11322号 8 (2013)
3)ファーマコゲノミクス解析による個別化薬物療法の推進
平塚真弘
医療薬学 39(6): 327-337 (2013)
2012
1) In vitro assessment of the allelic variants of cytochrome P450
Masahiro Hiratsuka
Drug Metab. Pharmacokinet. 27, 68-84 (2012)
2) ステロイドの基礎
平澤典保
ENTONI 139: 1-6 (2012)
3) ステロイド薬の基礎 ?適切な使用のために?
平澤典保
小児科 53: 203-210 (2012)
2011
1) ステロイドの作用機序と耐性化メカニズム
平澤典保
アレルギーの臨床（The Allergy in Practice）31: 1137-1141(2011)
2) キシレン、トリメチルベンゼンによる表皮からのTSLP産生誘導
平澤典保
臨床と免疫・アレルギー科 56: 478-484 (2011)
3) 抗炎症薬
平澤典保、Hong JangJa、木邑道夫、大内和雄
JOHNS 27: 1782-1786 (2011)
4) 薬学新時代の大学院教育
平澤典保、奥直人
薬学雑誌 131; 931 (2011)
5) 6年制の大学院教育：東北大学の場合
富岡佳久、平澤典保、永沼章
薬学雑誌 131: 932-938 (2011)
6) TSLP
平澤典保、Hong JangJa、木邑道夫、大内和雄
炎症と免疫
7) ステロイド薬の基礎
平澤典保
アレルギー 60;193-198 (2011)
8) 増悪化アレルギー性皮膚炎症におけるヒスタミンの役割
平澤典保、大内和雄
薬学雑誌 131;179-184 (2011)
2010
1) 臨床検査カレッジ：遺伝子検査、ファーマコゲノミクスと遺伝子多型診断
平塚真弘
医療と検査機器・試薬、33:197-201 (2010)
2) 遺伝子診療学（第2版）－遺伝子診断の進歩とゲノム治療の展望、薬剤感受性に関する遺伝子解析
平塚真弘、工藤睦、作山佳奈子
日本臨牀、6:269-274 (2010)
2008
1) 抗原非特異的炎症誘発によるアレルギー性皮膚炎の増悪化
平澤典保、大澤雄亮、石原研治、Hong JangJa, 瀬山敏雄、大内和雄
炎症と免疫16: 9-13（2008)
著書
・平澤典保
アレルギー治療薬 p238-242
気管支拡張薬・気管支喘息治療薬p242-244
免疫学的製剤（抗毒素、抗血清など）p244-245
HIV感染症（エイズ、AIDS)治療薬 p245-247
薬系免疫学 改訂第４版
植田正、前仲勝実編集 南江堂 (2022)
・平澤典保、川合眞一
第２章 A-4-1 副腎皮質ステロイド (p139-145)
第２章 A-4-2鎮痛薬（非ステロイド性抗炎症薬など）(p146-152)
臨床薬学シリーズ［薬理・病態・薬物治療］呼吸器／免疫・炎症・アレルギー／骨・関節
監修 乾賢一 中山書店 (2020)
・平澤典保
理系学生の指導：薬学部研究室のケース
もっと知りたい大学教員の仕事 大学を理解するための12章
羽田貴史編著 ナカニシヤ書店 (2015年)
・Kenji Ishihara, Noriyasu Hirasawa, Kazuo Ohuchi
Eosinophil cell lines
Eosinophils in Health and Disease, ed. by James J. Lee and Helene F. Rosenberg, Academic Press, p42-46
・平澤典保
免疫と医療 p207-215
薬系免疫学 改訂第二版 南江堂 編集 上田正、前仲勝実 (2012)
その他
・瀬川良佑
六年制薬学部から大学院に進学する意義を作り出す
医薬品相互作用研究 36: 207 (2013)
・佐藤大樹
４年制大学院１期生としての挑戦
医薬品相互作用研究 36: 208 (2013)
|
|
